Mosapride Citrate – Evidence‑Based Guidance

Clinical Positioning in the Treatment Algorithm

Mosapride should not be used as first‑line therapy for functional dyspepsia or gastro‑oesophageal reflux disease (GERD); it is reserved for later lines after acid‑suppression strategies have failed. 1
For functional dyspepsia, the recommended sequence is: (1) test for and eradicate Helicobacter pylori if present, (2) trial a proton‑pump inhibitor (PPI) for 4–8 weeks, and only then consider adding mosapride if symptoms persist. 1
In GERD, mosapride is indicated only as adjunctive therapy to a standard‑dose PPI (e.g., lansoprazole 30 mg daily); it should not be prescribed as monotherapy. 1

Mosapride demonstrates the greatest benefit for post‑prandial distress syndrome (PDS), a subset of functional dyspepsia, compared with other dyspepsia phenotypes. 1

Major gastro‑enterology societies assign a weak recommendation to mosapride for functional dyspepsia and GERD, citing low‑quality evidence; this contrasts with strong recommendations for PPIs and tricyclic antidepressants. 1

No specific dosing guidance exists for patients with moderate renal impairment; current dosing recommendations do not adjust for kidney function. 3

Mosapride has an excellent cardiac safety profile, with no reported QT‑interval prolongation, distinguishing it from other pro‑kinetics such as domperidone. 2